Clinical Research Lead-Oncology
Eli Lilly and CompanyFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Candidates must possess an MD degree or equivalent advanced training in Oncology, with preference given to those with 5 years of clinical research experience in biotechnology/pharmaceutical, clinical research organization, or academic research settings. Strong analytical, strategic, and implementation skills are required, along with the ability to work collaboratively in a team environment and lead cross-functional teams. Experience with site engagement and operations in clinical research settings, and a solid understanding of Good Clinical Practice and relevant regulations are also necessary.
The Associate Medical Director/Medical Director, Clinical Development will drive clinical development plans for precision medicine products, including genomic assays and algorithmic diagnostics, through their entire lifecycle, encompassing clinical validation and utility studies. This role involves providing medical expertise and subspecialty clinical context, designing and conducting studies, leading multidisciplinary teams, delivering presentations and publications for medical audiences, and engaging with external clinical research centers. The position also requires collaboration with various departments, including biostatistics, R&D scientists, and regulatory affairs, and contributing to the development of innovative clinical development strategies.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.